No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".
No 13F manager has reported this stock in the last 8 quarters.
None.
None.
No insider has filed a notice of proposed sale (Form 144) for Keenova Therapeutics plc in the last 12 months.
No 13F manager reports holding Keenova Therapeutics plc.
| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
AS
Investment Managers Series Trust II
|
$43.9K | 448 | 0.00% | 0.09% | July 31, 2026 |
|
FC
Advisors' Inner Circle III
|
$5.4K | 59 | 0.00% | 0.01% | June 30, 2026 |
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
SA
Steven A. Tananbaum
5%+ holder
13D · 22.4%
|
8.9M | 22.41% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
|
GA
GoldenTree Asset Management LP
5%+ holder
13D · 22.3%
|
8.8M | 22.28% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
5 more holders behind a free account
See every insider and 5%+ holder of Keenova Therapeutics plc.
Sign up freeLoading...